PROFILPELAJAR.COM

Tributyrin

Not to be confused with Tributyltin.
Tributyrin
Skeletal formula of butyrin
Ball-and-stick model of the butyrin molecule
Names
Systematic IUPAC name
Propane-1,2,3-triyl tributanoate
Other names
Tributyrin; Glyceryl tributyrate; Glycerol tributyrate; Glycerin tributyrate; NSC-661583; CoreBiome; ButyraGen
Identifiers
3D model (JSmol)
ChEBI
ChemSpider
DrugBank
ECHA InfoCard 100.000.410 Edit this at Wikidata
KEGG
UNII
  • InChI=1S/C15H26O6/c1-4-7-13(16)19-10-12(21-15(18)9-6-3)11-20-14(17)8-5-2/h12H,4-11H2,1-3H3
    Key: UYXTWWCETRIEDR-UHFFFAOYSA-N
  • CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC
Properties
C15H26O6
Molar mass 302.367 g·mol−1
Appearance Oily liquid with bitter taste[1]
Density 1.032 g/cm3[1]
Melting point −75 °C (−103 °F; 198 K)[1]
Boiling point 305 to 310 °C (581 to 590 °F; 578 to 583 K)[1]
Insoluble[1]
Hazards
Safety data sheet (SDS) Tributyrin MSDS, Fischer Scientific
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X markN verify (what is checkYX markN ?)

Tributyrin, also known as glyceryl tributyrate, is a triglyceride (fat) naturally present in butter.[2][3][4] It is an ester composed of three butyric acid (butyrate) moieties and glycerol.[1] It can be described as a liquid fat with an acrid taste. About 3 to 4% of butter is tributyrin, with butter being the richest known food source of tributyrin.[3] It is a slowly converted precursor or prodrug of the short-chain fatty acid (SCFA) butyric acid, which is a major product of gut bacteria and hence "postbiotic".[5]

Pharmacology

Tributyrin is a precursor or prodrug of the endogenous short-chain fatty acid (SCFA) butyric acid (butyrate).[4][2] It is stable and is rapidly absorbed and gradually converted into butyric acid.[2] Tributyrin is not broken down by gastric juice and is slowly converted into butyric acid and glycerol by pancreatic lipases in the gut.[6] In addition, tributyrin is more lipophilic than butyric acid and is taken up into cells much more readily in comparison.[4] Butyric acid itself has an extremely short elimination half-life of seconds to minutes among other limitations, which makes its own use impractical.[2]

Butyric acid, the active form of tributyrin, has a large variety of biological effects.[5] It is an agonist of the FFAR2 (GPR43), FFAR3 (GPR41), and GPR109A and a histone deacetylase (HDAC) inhibitor of HDAC classes I and II.[5] In addition, butyric acid is the preferred energy source for colonocytes, and has been found to provide approximately 70% of total energy needs for colonocytes in mice.[5] Butyrate plays a key role in gut homeostasis and has anti-inflammatory effects among others.[5] Tributyrin is described as an HDAC inhibitor similarly to butyric acid.[7][8]

Tributyrin has been found to reverse gut microbiota dysbiosis and intestinal injury and inflammation induced by antibiotics in rodents.[4][6] This included increasing potentially beneficial SCFA-producing bacteria such as Muribaculaceae and Bifidobacterium and decreasing potentially pathogenic bacteria such as Bacteroidetes and Enterococcus.[6] One means by which SCFAs like butyrate may mediate such effects is by decreasing intestinal pH.[9] In accordance with the observed intestinal bacterial changes, tributyrin increased levels of the SFCAs butyric acid, acetic acid (acetate), and propionic acid (propionate).[6] The effects of tributyrin and butyrate appear to be dose-dependent, with low concentrations promoting the intestinal barrier and inhibiting inflammation while high concentrations can do the opposite via induction of apoptosis.[4][6] In addition to reversing antibiotic-induced dysbiosis, tributyrin has been found to strongly reduce Clostridium difficile infection in rodents.[4][10] Coadministration of tributyrin with the probiotics Limosilactobacillus reuteri and Lacticaseibacillus rhamnosus has been found to synergistically increase butyrate levels in humans ex vivo as well.[11][12]

In vitro, butyric acid is known to activate the brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrkB) signaling pathway via its HDAC inhibition.[13]

Other uses

Tributyrin is used in microbiological laboratories to identify the bacterium Moraxella catarrhalis.[14]

Research

Tributyrin was under formal clinical development for the treatment of solid tumors in the late 1990s, but no further development was subsequently reported.[15]

See also

References

  1. ^ a b c d e f Budavari, Susan, ed. (1996). The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals (12th ed.). Merck. ISBN 0911910123.
  2. ^ a b c d Heidor R, Ortega JF, de Conti A, Ong TP, Moreno FS (December 2012). "Anticarcinogenic actions of tributyrin, a butyric acid prodrug". Curr Drug Targets. 13 (14): 1720–1729. doi:10.2174/138945012804545443. PMID 23140283.
  3. ^ a b Wächtershäuser A, Stein J (August 2000). "Rationale for the luminal provision of butyrate in intestinal diseases". Eur J Nutr. 39 (4): 164–171. doi:10.1007/s003940070020. PMID 11079736. A direct source of butyrate is the diet, where it is present at low levels in many fruits and vegetables, but its richest source is from milk fat (butter) which contains 3–4 % butyrate as glycerol esters, termed tributyrin
  4. ^ a b c d e f Yu J, Li W, Xu Y, Tang J (June 2026). "Gut microbiota-derived short-chain fatty acids (SCFAs): immunomodulatory effects and therapeutic potential in infections". Clin Microbiol Rev e00368-25: e0036825. doi:10.1128/cmr.00368-25. PMID 42267834.
  5. ^ a b c d e Mukhopadhya I, Louis P (October 2025). "Gut microbiota-derived short-chain fatty acids and their role in human health and disease". Nat Rev Microbiol. 23 (10): 635–651. doi:10.1038/s41579-025-01183-w. PMID 40360779.
  6. ^ a b c d e Yang N, Lan T, Han Y, et al. (2023). "Tributyrin alleviates gut microbiota dysbiosis to repair intestinal damage in antibiotic-treated mice". PLoS One. 18 (7) e0289364. Bibcode:2023PLoSO..1889364Y. doi:10.1371/journal.pone.0289364. PMC 10389721. PMID 37523400.
  7. ^ Rocchi P, Tonelli R, Camerin C, et al. (June 2005). "p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells". Oncol Rep. 13 (6): 1139–1144. PMID 15870934.
  8. ^ Gerunova LK, Gerunov TV, P'yanova LG, et al. (March 2024). "Butyric acid and prospects for creation of new medicines based on its derivatives: a literature review". J Vet Sci. 25 (2) e23. doi:10.4142/jvs.23230. PMC 10990906. PMID 38568825.
  9. ^ Zhao X, Liu S, Li S, et al. (April 2024). "Unlocking the power of postbiotics: A revolutionary approach to nutrition for humans and animals". Cell Metab. 36 (4): 725–744. doi:10.1016/j.cmet.2024.03.004. PMID 38569470.
  10. ^ Ouyang ZR, Niu XR, Wang WG, Zhao JH (June 2022). "The role of short-chain fatty acids in Clostridioides difficile infection: A review". Anaerobe. 75 102585. doi:10.1016/j.anaerobe.2022.102585. PMID 35545183.
  11. ^ Feng J, Cen Q, Cui Y, et al. (January 2025). "Lactobacillus rhamnosus: An emerging probiotic with therapeutic potential for depression". Pharmacol Res. 211 107541. doi:10.1016/j.phrs.2024.107541. PMID 39653301. Supplementation with tributyrin (TB) significantly raises butyrate levels, and L. rhamnosus ATCC 53103 (LGG) may enhance butyrate production by modulating the gut microbiota [117].
  12. ^ Van den Abbeele P, Goggans M, Deyaert S, et al. (March 2023). "Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo". Int J Mol Sci. 24 (6): 5859. doi:10.3390/ijms24065859. PMC 10054277. PMID 36982942.
  13. ^ Korenblik V, Schilder NK, de Lange IG, et al. (February 2026). "From gut to glee: Is butyrate a promising antidepressant? A systematic review and mechanistic insights". Brain Behav Immun. 132 106237. doi:10.1016/j.bbi.2025.106237. PMID 41429215.
  14. ^ Pérez, José L.; Pulido, Angeles; Pantozzi, Florencia; Martin, Rogelio (October 1990). "Butyrate esterase (4-methylumbelliferyl butyrate) spot test, a simple method for immediate identification of Moraxella (Branhamella) catarrhalis corrected". Journal of Clinical Microbiology. 28 (10). Washington, DC: American Society for Microbiology: 2347–2348. doi:10.1128/jcm.28.10.2347-2348.1990. ISSN 1098-660X. PMC 268174. PMID 2121784.
  15. ^ "Tributyrin". AdisInsight. 23 September 2021. Retrieved 3 July 2026.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.